Drug intelligence / Profile preview

M101

Development stage: Preclinical
Lead developer: RetroVirox
Modality: Small Molecules

Overview

M101 is a preclinical-stage small molecule immunomodulator being developed by RetroVirox. It is designed to block the HIV-mediated downmodulation of major histocompatibility complex class I (MHC-I) on infected cells. By restoring MHC-I surface expression, M101 enables CD8+ cytotoxic T lymphocytes (CTLs) to recognize and eliminate HIV-infected cells. This mechanism is being investigated as part of a 'kick and kill' HIV eradication strategy to target and clear the latent viral reservoir.

Targets

MHC I (MHC class I})

Beyond the preview

Go deeper on M101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on M101.